ADC Therapeutics SA (ADCT) Stock: Buy, Sell, or Hold?
ADCT - ADC Therapeutics SA
$1.07
-0.04 (-3.60%)
▼
5d:
-18.94%
30d:
-13.01%
90d:
+0.94%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ADCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ADCT is down 18.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ADCT is down 18.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ADCT is currently trading at $1.07, which is considered slightly high relative to its 30-day fair value range of $1.02 to $1.24.
Technical Outlook: Technically, ADCT is in a strong downtrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: ADCT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+211.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADCT is in a strong downtrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: ADCT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+211.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.02 -
$1.24
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 211.5% below Wall St target ($3.33)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.02 -
$1.24
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.37
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.58
Wall Street Target
$3.33
(+211.5%)
Revenue Growth (YoY)
2.2%
Profit Margin
-121.8%
Share & Embed Analysis
Last updated: September 12, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Redmile Group, Llc
SELL
2529491 shares
2026-04-02
Redmile Group, Llc
SELL
2634506 shares
2026-04-02
Redmile Group, Llc
SELL
162517 shares
2026-04-01
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
